• prostate cancer;
  • 3 T MRI;
  • diffusion-weighted imaging (DWI);
  • dynamic contrast enhanced imaging



To evaluate the diagnostic ability of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced imaging (DCEI) in combination with T2-weighted imaging (T2WI) for the detection of prostate cancer using 3 T magnetic resonance imaging (MRI) with a phased-array body coil.

Materials and Methods:

Fifty-three patients with elevated serum levels of prostate-specific antigen (PSA) were evaluated by T2WI, DWI, and DCEI prior to needle biopsy. The obtained data from T2WI alone (protocol A), a combination of T2WI and DWI (protocol B), a combination T2WI and DCEI (protocol C), and a combination of T2WI plus DWI and DCEI (protocol D) were subjected to receiver operating characteristic (ROC) curve analysis.


The sensitivity, specificity, accuracy, and area under the ROC curve (Az) for region-based analysis were: 61%, 91%, 84%, and 0.8415, respectively, in protocol A; 76%, 94%, 90%, and 0.8931, respectively, in protocol B; 77%, 93%, 89%, and 0.8655, respectively, in protocol C; and 81%, 96%, 92%, and 0.8968, respectively in protocol D. ROC analysis revealed significant differences between protocols A and B (P = 0.0008) and between protocols A and D (P = 0.0004).


In patients with elevated PSA levels the combination of T2WI, DWI, DCEI using 3 T MRI may be a reasonable approach for the detection of prostate cancer. J. Magn. Reson. Imaging 2010;31:625–631. © 2010 Wiley-Liss, Inc.